Previous 10 | Next 10 |
P/E (5.61), EV/EBITDA (9.28), and Price/Sales (5.37) are 30-80% lower than the sector medians. Balance sheet of IRWD has been steadily improving over the past several years. Revenue has grown since 2016 (CAGR of 21.10%). I don’t believe this low valuation is justified, ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Covid-19 pandemic brought a renewed interest into the healthcare sector, and with the surging Delta variant raging across the country, that interest isn’t expected to dissipate anytime soon. Due to that attentio...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS ® (linaclotide) based on clinical safety data that has been generated thus far in pediatric ...
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) traded at a new 52-week high today of $14.14. Approximately 166,000 shares have changed hands today, as compared to an average 30-day volume of 1.8 million shares. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is currently priced 78.8% above its ...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2021 Earnings Conference Call August 05, 2021 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Jason Rickard - Chief Operating Officer Mike Shetzline - Chief Medical Officer Conference ...
Image source: The Motley Fool. Ironwood Pharmaceuticals, inc (NASDAQ: IRWD) Q2 2021 Earnings Call Aug 5, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals, inc (IRWD) Q2 2021 Earnings Call Tra...
Ironwood Pharmaceuticals (NASDAQ:IRWD): Q2 Non-GAAP EPS of $0.34 beats by $0.12; GAAP EPS of $2.39 beats by $2.16. Revenue of $104.03M (+16.3% Y/Y) beats by $11.56M. Updated 2021 Guidance: Total revenue expected to be between $390M to $410M, from prior estimate of $370M to $385M. Re...
– LINZESS ® (Iinaclotide) U.S. net sales of $259 million, an increase of 18% year-over-year – – Total revenue of $104 million, an increase of 16% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $100 million –...
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) traded at a new 52-week high today of $13.64. Approximately 166,000 shares have changed hands today, as compared to an average 30-day volume of 2.1 million shares. In the past 52 weeks, shares of Ironwood Pharmaceuticals Inc. have traded betwee...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...